Temozolomide

also known as TMZ · Temodar · Temodar-Temozolomide · Temodal · SCH 52365 · Temozolomide - Temodar · benzolamide · Temodar (R) · +6 more

Small molecule targets AGT, MGMT via inhibition

Developed for: glioblastoma · central nervous system neoplasm · gliosarcoma · melanoma · neuroblastoma · anaplastic astrocytoma · glioma · cutaneous melanoma
+217 more
· small cell lung carcinoma · metastatic malignant neoplasm in the brain · oligodendroglioma · primary central nervous system lymphoma · adult glioblastoma · cancer · malignant glioma · brain cancer · brain neoplasm · Ewing sarcoma · metastatic malignant neoplasm · astrocytoma (excluding glioblastoma) · central nervous system cancer · medulloblastoma · metastatic melanoma · non-small cell lung carcinoma · giant cell glioblastoma · neuroendocrine neoplasm · anaplastic oligodendroglioma · breast cancer · colorectal cancer · lymphoma · cancer of unknown primary site · childhood malignant neoplasm · ependymoma · oligoastrocytoma · ovarian cancer · rhabdomyosarcoma · sarcoma · diffuse intrinsic pontine glioma · IDH-wildtype glioblastoma · pancreatic neuroendocrine tumor · lung cancer · primary brain neoplasm · refractory malignant neoplasm · anaplastic oligoastrocytoma · brain glioblastoma · childhood medulloblastoma · grade III glioma · neuroendocrine carcinoma · brain glioma · brain stem glioma · childhood cerebral astrocytoma · grade II glioma · low-grade astrocytoma · mixed glioma · pancreatic endocrine carcinoma · pineoblastoma · soft tissue sarcoma · supratentorial primitive neuroectodermal tumor · atypical teratoid rhabdoid tumor · childhood cerebellar astrocytic neoplasm · childhood germ cell tumor · ependymoblastoma · gastrointestinal stromal tumor · glucagonoma · kidney cancer · leiomyosarcoma of the corpus uteri · low grade glioma · lung neuroendocrine neoplasm · medulloepithelioma · metastatic neoplasm · neoplasm · ocular melanoma · pancreatic insulinoma · rectal cancer · somatostatinoma · benign meningioma · childhood brain stem glioma · childhood central nervous system germ cell tumor · childhood choroid plexus neoplasm · childhood oligodendroglioma · childhood spinal cord tumor · craniopharyngioma · diffuse astrocytoma · diffuse glioma, H3 G34 mutant · diffuse midline glioma, H3 K27M-mutant · fallopian tube cancer · ganglioneuroblastoma · gastrin-producing neuroendocrine tumor · grade II meningioma · grade III meningioma · hepatocellular carcinoma · high grade astrocytic tumor · leukemia · liver cancer · mucosal melanoma · neoplastic meningitis · optic pathway glioma · osteosarcoma · pancreatic neuroendocrine neoplasm · paraganglioma · pediatric infratentorial ependymoma · pediatric supratentorial ependymoma · pheochromocytoma · pituitary gland adenoma · PPoma · primary peritoneal carcinoma · primitive neuroectodermal tumor · retinoblastoma · skin cancer · spinal cord neoplasm · subependymal giant cell astrocytoma · testicular germ cell tumor · uveal melanoma · Wilms tumor · acral lentiginous melanoma · acute myeloid leukemia · acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent · acute myeloid leukemia, inv(16)(p13.1;q22) · acute myeloid leukemia, t(15;17)(q24;q21) · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute myeloid leukemia, t(8;21)(q22; q22.1) · acute myeloid leukemia, t(9;11)(p21.3;q23.3) · adenocarcinoma · adrenal cortex carcinoma · adrenal gland pheochromocytoma · adult anaplastic ependymoma · adult brainstem glioma · alveolar rhabdomyosarcoma · B-cell adult acute lymphocytic leukemia · B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) · bone cancer · brain oligodendroglioma · breast neoplasm · carcinoid tumor · castration-resistant prostate carcinoma · central nervous system non-hodgkin lymphoma · central nervous system primitive neuroectodermal neoplasm · cerebellar astrocytoma · childhood ependymoma · choroid plexus neoplasm · chronic myelomonocytic leukemia · clear cell papillary renal cell carcinoma · collecting duct carcinoma · colorectal adenocarcinoma · colorectal carcinoma · colorectal neoplasm · cutaneous neuroendocrine carcinoma · desmoplastic small round cell tumor · digestive system neuroendocrine neoplasm · digestive system neuroendocrine tumor, grade 1/2 · embryonal rhabdomyosarcoma · embryonal tumor with multilayered rosettes · endometrial cancer · esophageal cancer · Ewing sarcoma/peripheral primitive neuroectodermal tumor · extragonadal germ cell tumor · gastric neuroendocrine neoplasm · gastroesophageal junction adenocarcinoma · gliomatosis cerebri · head and neck cancer · head and neck neoplasm · hematopoietic and lymphoid system neoplasm · HER2 positive breast carcinoma · hereditary leiomyomatosis and renal cell cancer · hereditary papillary renal cell carcinoma · high grade malignant neoplasm · IDH-wildtype anaplastic astrocytoma · intestinal neuroendocrine neoplasm · iris melanoma · large cell carcinoma · large cell neuroendocrine carcinoma · leiomyosarcoma · lung disorder · malignant adrenal gland pheochromocytoma · malignant childhood germ cell neoplasm · malignant pancreatic neoplasm · medium/large size posterior uveal melanoma · medullary thyroid gland carcinoma · medulloblastoma non-WNT/non-SHH group 3 · medulloblastoma non-WNT/non-SHH group 4 · medulloblastoma SHH activated · meningioma · mesothelioma · metastatic prostate carcinoma · multiple endocrine neoplasia type 1 · multiple endocrine neoplasia type 2A · multiple endocrine neoplasia type 2B · myelodysplastic syndrome · myeloid leukemia · neoplasm of esophagus · neurofibromatosis type 1 · nodular ganglioneuroblastoma · non-functional pancreatic neuroendocrine tumor · non-Hodgkin lymphoma · ocular melanoma with extraocular extension · oligodendroglial tumor · optic nerve glioma · pancreatic delta cell neuroendocrine tumor · pancreatic gastrin-producing neuroendocrine tumor · pancreatic insulin-producing neuroendocrine tumor · pediatric lymphoma · pediatric meningioma · peripheral primitive neuroectodermal tumor · pheochromocytoma-paraganglioma · prostate adenocarcinoma · prostate cancer · rhabdoid tumor · small cell carcinoma · small intestine neuroendocrine tumor, well differentiated, low or intermediate grade · small size posterior uveal melanoma · soft tissue neoplasm · squamous cell carcinoma · supratentorial cancer · T-cell adult acute lymphocytic leukemia · thymic neuroendocrine tumor · triple-negative breast carcinoma · tubulocystic renal cell carcinoma · VIPoma · Zollinger-Ellison syndrome · acute myeloid leukemia with 11q23 abnormalities · brain astrocytoma · childhood low-grade glioma · diffuse low-grade glioma, MAPK pathway–altered · hepatoblastoma · malignant germ cell tumor
Investigated by: National Cancer Institute (NCI) · Schering-Plough · M.D. Anderson Cancer Center · Memorial Sloan Kettering Cancer Center · Merck Sharp & Dohme LLC · Duke University
+506 more
· Genentech, Inc. · European Organisation for Research and Treatment of Cancer - EORTC · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Dana-Farber Cancer Institute · University of California, San Francisco · Radiation Therapy Oncology Group · Children's Oncology Group · Northwestern University · Bristol-Myers Squibb · Gustave Roussy, Cancer Campus, Grand Paris · Jonsson Comprehensive Cancer Center · NRG Oncology · Pfizer · Massachusetts General Hospital · Mayo Clinic · AbbVie · Alliance for Clinical Trials in Oncology · Bayer · NYU Langone Health · Sun Yat-sen University · Assistance Publique - Hôpitaux de Paris · Brigham and Women's Hospital · Chinese Academy of Medical Sciences · Eisai Inc. · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · GlaxoSmithKline · Novartis · NovoCure Ltd. · Peking University Cancer Hospital & Institute · Abbott · Abramson Cancer Center at Penn Medicine · Asan Medical Center · Beth Israel Deaconess Medical Center · Cancer Research UK · Case Comprehensive Cancer Center · Eli Lilly and Company · H. Lee Moffitt Cancer Center and Research Institute · National Cancer Institute, France · National Institutes of Health (NIH) · Peking Union Medical College Hospital · Second Affiliated Hospital, School of Medicine, Zhejiang University · Stanford University · Washington University School of Medicine · Zhejiang Cancer Hospital · BeiGene · Beijing Sanbo Brain Hospital · Beijing Tiantan Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Celgene Corporation · Centre Leon Berard · Centre Oscar Lambret · Children's Cancer and Leukaemia Group · Children's Hospital Los Angeles · City of Hope Medical Center · Columbia University · Dartmouth-Hitchcock Medical Center · Eastern Cooperative Oncology Group · Fox Chase Cancer Center · Georgetown University · Grupo Español de Investigación en Neurooncología · Haukeland University Hospital · Heidelberg University · Herbert Irving Comprehensive Cancer Center · Hoffmann-La Roche · Huashan Hospital · Institut Curie · Institute of Cancer Research, United Kingdom · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Kentuckiana Cancer Institute · Keryx / AOI Pharmaceuticals, Inc. · Merck KGaA, Darmstadt, Germany · Millennium Pharmaceuticals, Inc. · Novartis Pharmaceuticals · Ohio State University Comprehensive Cancer Center · all 512 on the full record

Regulatory milestones approvals, filings & regulatory actions · 6 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Refused (EMA)	EU (EMA)	Kizfizo	—	2025-05-02	europa.eu ↗
Label expansions (3)	US (FDA)	TEMODAR	—	2003-03-11 – 2023-09-14	fda.gov ↗
Approved	US (FDA)	TEMODAR	—	1999-08-11	fda.gov ↗
Approved	EU (EMA)	Temodal	—	1999-01-26	europa.eu ↗

Trials 657 · started per year

today

EU approved 1999

US approved 1999

199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 013 trials · 1 met primary
Phase 0	NCT06942039	Sep 2025 → Dec 2030 expected	atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5	C17 Council	Recruiting	No outcome recorded
Phase 0	NCT07025226	Aug 2025 → Sep 2028 expected	glioma	Mayo Clinic	Recruiting	No outcome recorded
Phase 0	NCT03796507	Sep → Dec 2021	brain glioma	University of Rochester	Withdrawn	No outcome recorded
Phase 0	NCT04135807	Mar 2020 → Jan 2028 expected	anaplastic astrocytoma, anaplastic oligodendroglioma, brain oligodendroglioma, glioblastoma	Oliver Jonas	Recruiting	No outcome recorded
Phase 0	NCT03477110	May 2018 → Apr 2021	glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Completed	Met primary
Phase 0	NCT03291990	Oct 2017 → Aug 2020	glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 0	NCT03189706	Jun 2017 → Jun 2027 expected	neuroblastoma	Memorial Sloan Kettering Cancer Center	Active not recruiting	No outcome recorded
Phase 0	NCT02976441	Jan 2017 → Feb 2018	astrocytoma (excluding glioblastoma), brain stem glioma, ependymoma, mixed glioma +2	Washington University School of Medicine	Withdrawn	No outcome recorded
Phase 0	NCT02766270	Sep 2016 → Dec 2017	glioma	Beijing Tiantan Hospital	Unknown	No outcome recorded
Phase 0	NCT02389738	Feb 2015 → Feb 2016	—	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 0	NCT01957956	Nov 2013 → Nov 2016	giant cell glioblastoma, gliosarcoma	Mayo Clinic	Completed	No outcome recorded
Phase 0	NCT01189643	Aug 2010 → Aug 2027 expected	desmoplastic small round cell tumor	Memorial Sloan Kettering Cancer Center	Active not recruiting	No outcome recorded
Phase 0	NCT00890786	May 2009 → Oct 2014	diffuse intrinsic pontine glioma	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded

Phase 1122 trials
Phase 1	NCT07457307	Jun 2026 → Jun 2028 expected	malignant glioma	NYU Langone Health	Not yet recruiting	No outcome recorded
Phase 1	NCT07194044	Feb 2026 → Oct 2030 expected	Ewing sarcoma	H. Lee Moffitt Cancer Center and Research Institute	Recruiting	No outcome recorded
Phase 1	NCT06931626	Aug 2025 → Oct 2026 expected	small cell lung carcinoma	Nerviano Medical Sciences	Recruiting	No outcome recorded
Phase 1	NCT06710821	Dec 2024 → Dec 2025 overdue	—	Yizhuo Zhang	Not yet recruiting	No outcome recorded
Phase 1	NCT06475235	Oct 2024 → Dec 2026 expected	primary central nervous system lymphoma	Dana-Farber Cancer Institute	Recruiting	No outcome recorded
Phase 1	NCT06410248	Jul 2024 → Jul 2026 overdue	IDH-wildtype glioblastoma, grade II glioma, grade III glioma	Northwestern University	Recruiting	No outcome recorded
Phase 1	NCT06418113	Mar 2024 → Nov 2026 expected	IDH-wildtype glioblastoma, brain cancer	Hospital San Carlos, Madrid	Recruiting	No outcome recorded
Phase 1	NCT04967690	Jan 2024 → Jul 2025	glioblastoma	Double Bond Pharmaceutical AB	Unknown	No outcome recorded
Phase 1	NCT05879367	Jul 2023 → Jun 2026 overdue	IDH-wildtype glioblastoma, astrocytoma (excluding glioblastoma)	Orbus Therapeutics, Inc.	Recruiting	No outcome recorded
Phase 1	NCT05698524	Jun 2023 → Jul 2027 expected	anaplastic astrocytoma, anaplastic oligodendroglioma, gliosarcoma	University of Nebraska	Recruiting	No outcome recorded
Show all 122 trials opens the full record — a long page
Phase 1/298 trials · 1 met primary
Phase 1/2	NCT07859059	Jun 2027 → Jun 2030 expected	gliosarcoma	University of Nebraska	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07811297	Sep 2026 → Sep 2030 expected	endometrium neoplasm, glioblastoma, ovarian neoplasm, soft tissue sarcoma	Advenchen Pharmaceuticals, LLC.	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07569042	Apr 2026 → Sep 2029 expected	brain cancer	Novelwise Pharmaceutical Corporation	Recruiting	No outcome recorded
Phase 1/2	NCT06681220	Feb 2026 → Dec 2029 expected	small cell lung carcinoma	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 1/2	NCT07391215	Jan 2026 → Jan 2029 expected	glioblastoma	Institute of Cancer Research, United Kingdom	Recruiting	No outcome recorded
Phase 1/2	NCT07141771	Dec 2025 → Jun 2030 expected	small cell lung carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07243470	Nov 2025 → Oct 2029 expected	central nervous system cancer, glioma	Centre Leon Berard	Recruiting	No outcome recorded
Phase 1/2	NCT06721689	Mar 2025 → Apr 2030 expected	neuroblastoma, refractory malignant neoplasm, rhabdomyosarcoma	Theodore Laetsch	Recruiting	No outcome recorded
Phase 1/2	NCT06703255	Jan 2025 → Dec 2026 expected	glioma	Hangzhou Hanx Biopharmaceuticals, Ltd.	Recruiting	No outcome recorded
Phase 1/2	NCT06630260	Nov 2024 → Sep 2029 expected	diffuse glioma, H3 G34 mutant, glioblastoma	Institute of Cancer Research, United Kingdom	Recruiting	No outcome recorded
Phase 1/2	NCT07599371	Oct 2024 → Oct 2027 expected	glioma	The First Affiliated Hospital of Zhengzhou University	Recruiting	No outcome recorded
Phase 1/2	NCT06258018	Sep 2024 → Dec 2026 expected	malignant glioma	Armando Santoro, MD	Not yet recruiting	No outcome recorded
Phase 1/2	NCT06208657	Jul 2024 → Dec 2030 expected	brain cancer, childhood malignant neoplasm, refractory malignant neoplasm	Australian & New Zealand Children's Haematology/Oncology Group	Recruiting	No outcome recorded
Phase 1/2	NCT06186440	Jan → Dec 2024	brain glioblastoma	Zhongnan Hospital	Unknown	No outcome recorded
Phase 1/2	NCT05691491	Sep 2023 → Mar 2027 expected	colorectal carcinoma, hematopoietic and lymphoid system neoplasm, metastatic malignant neoplasm	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1/2	NCT06038461	Sep 2023 → Sep 2026 overdue	neuroendocrine neoplasm	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Recruiting	No outcome recorded
Phase 1/2	NCT05664243	Sep 2023 → Dec 2025 overdue	glioblastoma	In8bio Inc.	Active not recruiting	No outcome recorded
Phase 1/2	NCT05983237	Aug 2023 → Dec 2026 expected	melanoma	Jun Guo	Recruiting	No outcome recorded
Phase 1/2	NCT04077866	Jun 2023 → Jun 2025	glioblastoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 1/2	NCT04796012	Apr 2023 → Jan 2027 expected	rhabdomyosarcoma	University of Texas Southwestern Medical Center	Recruiting	No outcome recorded
Phase 1/2	NCT05588453	Mar 2023 → Apr 2027 expected	cutaneous melanoma, metastatic malignant neoplasm in the brain, metastatic melanoma	Kari Kendra	Recruiting	No outcome recorded
Phase 1/2	NCT05728619	Feb 2023 → Aug 2024	small cell lung carcinoma	Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.	Unknown	No outcome recorded
Phase 1/2	NCT05663125	Dec 2022 → Dec 2023	glioblastoma	Beijing Tiantan Hospital	Unknown	No outcome recorded
Phase 1/2	NCT05384821	Sep 2022 → May 2028 expected	Wilms tumor	Centre Oscar Lambret	Recruiting	No outcome recorded
Phase 1/2	NCT04211675	Sep 2022 → Dec 2026 expected	neuroblastoma	Nationwide Children's Hospital	Active not recruiting	No outcome recorded
Phase 1/2	NCT05417594	Jun 2022 → Feb 2028 expected	high grade malignant neoplasm	AstraZeneca	Recruiting	No outcome recorded
Phase 1/2	NCT04910022	Dec 2021 → May 2027 expected	glioblastoma	Nerviano Medical Sciences	Active not recruiting	No outcome recorded
Phase 1/2	NCT05027386	Aug 2021 → Feb 2026	neuroblastoma	Sun Yat-sen University	Completed	No outcome recorded
Phase 1/2	NCT04689347	Jan 2021 → Apr 2026 overdue	colorectal cancer	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Recruiting	No outcome recorded
Phase 1/2	NCT04238819	Nov 2020 → Mar 2024	refractory malignant neoplasm	Eli Lilly and Company	Completed	No outcome recorded
Phase 1/2	NCT04547621	Sep 2020 → Jan 2023	malignant glioma	Huashan Hospital	Unknown	No outcome recorded
Phase 1/2	NCT04434482	Aug 2020 → Apr 2024	small cell lung carcinoma	Impact Therapeutics, Inc.	Completed	No outcome recorded
Phase 1/2	NCT04400188	Jun 2020 → Jan 2022	small cell lung carcinoma	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1/2	NCT04421378	Jun 2020 → Jul 2023	glioblastoma	Karyopharm Therapeutics Inc	Terminated	No outcome recorded
Phase 1/2	NCT03914742	Feb 2020 → Oct 2023	glioblastoma, grade II glioma, grade III glioma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 1/2	NCT04267146	Jul 2019 → Nov 2024	malignant glioma	Gustave Roussy, Cancer Campus, Grand Paris	Completed	No outcome recorded
Phase 1/2	NCT04019327	Jul 2019 → Dec 2025	castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT04119674	Mar 2019 → Aug 2022	glioblastoma	Zhejiang Cancer Hospital	Completed	No outcome recorded
Phase 1/2	NCT03830918	Mar 2019 → Jan 2027 expected	small cell lung carcinoma	Jonsson Comprehensive Cancer Center	Active not recruiting	No outcome recorded
Phase 1/2	NCT03782415	Dec 2018 → Aug 2023	glioblastoma	MediciNova	Completed	No outcome recorded
Phase 1/2	NCT03554473	Sep 2018 → Jun 2022	small cell lung carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT03643549	Aug 2018 → Jun 2025	glioblastoma	Haukeland University Hospital	Unknown	No outcome recorded
Phase 1/2	NCT03466450	Mar 2018 → Nov 2023	glioblastoma	Grupo Español de Investigación en Neurooncología	Completed	No outcome recorded
Phase 1/2	NCT03119064	Nov 2017 → Apr 2020	glioblastoma	Brown University	Terminated	No outcome recorded
Phase 1/2	NCT03212742	Sep 2017 → Sep 2026 overdue	malignant glioma	Centre Francois Baclesse	Active not recruiting	No outcome recorded
Phase 1/2	NCT03150862	Jul 2017 → Mar 2021	brain cancer	BeiGene	Completed	No outcome recorded
Phase 1/2	NCT03174197	Jun 2017 → Sep 2025	gliosarcoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT03213002	Jun 2017 → Jun 2028 expected	adult glioblastoma, brain glioma, primary brain neoplasm	Northwell Health	Recruiting	No outcome recorded
Phase 1/2	NCT02942264	Dec 2016 → Aug 2020	astrocytoma (excluding glioblastoma), gliosarcoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1/2	NCT02770378	Nov 2016 → Oct 2018	glioblastoma	University of Ulm	Completed	No outcome recorded
Phase 1/2	NCT02813135	Aug 2016 → Feb 2031 expected	childhood malignant neoplasm	Gustave Roussy, Cancer Campus, Grand Paris	Recruiting	No outcome recorded
Phase 1/2	NCT02661282	Jun 2016 → Feb 2022	cytomegalovirus infection, gliosarcoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT02446704	Oct 2015 → Dec 2022	small cell lung carcinoma	Zofia Piotrowska	Unknown	No outcome recorded
Phase 1/2	NCT02590263	Aug 2015 → Aug 2020	glioblastoma	AbbVie	Completed	No outcome recorded
Phase 1/2	NCT02494804	Jul 2015 → Jul 2028 expected	malignant glioma	The First People's Hospital of Changzhou	Not yet recruiting	No outcome recorded
Phase 1/2	NCT02385136	Apr 2015 → Dec 2016	non-small cell lung carcinoma	Zhejiang Cancer Hospital	Unknown	No outcome recorded
Phase 1/2	NCT01985087	Sep 2014 → May 2025 overdue	glioblastoma	University of Louisville	Active not recruiting	No outcome recorded
Phase 1/2	NCT02065466	Jul 2014 → Feb 2015	metastatic malignant neoplasm in the brain, metastatic melanoma	University of Arizona	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1/2	NCT02116777	May 2014 → Dec 2018	Ewing sarcoma/peripheral primitive neuroectodermal tumor, central nervous system cancer, childhood malignant neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT02052648	Mar 2014 → Apr 2018	gliosarcoma	NewLink Genetics Corporation	Completed	No outcome recorded
Phase 1/2	NCT01590082	Nov 2012 → Jul 2015	melanoma	M.D. Anderson Cancer Center	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT01601184	Jun 2012 → Sep 2017	medulloblastoma SHH activated	Centre Leon Berard	Terminated	No outcome recorded
Phase 1/2	NCT01601535	May 2012 → Jul 2018	neuroblastoma	New Approaches to Neuroblastoma Therapy Consortium	Completed	No outcome recorded
Phase 1/2	NCT01514201	Feb 2012 → Mar 2018	anaplastic astrocytoma, brain stem glioma, fibrillary astrocytoma, giant cell glioblastoma +2	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT01465659	Dec 2011 → Jul 2018	pancreatic delta cell neuroendocrine tumor, pancreatic endocrine carcinoma, pancreatic gastrin-producing neuroendocrine tumor, pancreatic insulin-producing neuroendocrine tumor	Northwestern University	Completed	No outcome recorded
Phase 1/2	NCT01110876	Jun 2011 → Jul 2014	brain cancer, glioblastoma	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 1/2	NCT01196416	Aug 2010 → Aug 2015	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT01026493	Jul 2010 → May 2014	central nervous system neoplasm	Radiation Therapy Oncology Group	Completed	No outcome recorded
Phase 1/2	NCT01120639	Apr 2010 → Nov 2016	glioblastoma	Stanford University	Completed	No outcome recorded
Phase 1/2	NCT00925132	Dec 2009 → Nov 2014	metastatic melanoma	University of Iowa	Terminated	No outcome recorded
Phase 1/2	NCT01044966	Sep 2009 → Aug 2013	glioblastoma, primary brain neoplasm	Medical University of South Carolina	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00961844	Aug 2009 → Jun 2012	metastatic melanoma	Steinar Aamdal	Terminated	No outcome recorded
Phase 1/2	NCT00731731	Jul 2009 → Feb 2014	adult glioblastoma, giant cell glioblastoma, gliosarcoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT00669669	Feb 2009 → Jul 2018	gliosarcoma	Fred Hutchinson Cancer Center	Terminated	No outcome recorded Stop: Business
Phase 1/2	NCT00687765	Jul 2008 → Jun 2015	glioblastoma	Sanofi	Completed	No outcome recorded
Phase 1/2	NCT00715793	Jun 2008 → May 2015	melanoma	Hussein Tawbi	Completed	No outcome recorded
Phase 1/2	NCT00576680	May 2008 → Mar 2019	pancreatic neuroendocrine tumor	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 1/2	NCT00555399	Nov 2007 → Jan 2020	glioblastoma	M.D. Anderson Cancer Center	Terminated	No outcome recorded Stop: Business
Phase 1/2	NCT00811759	Jun 2007 → May 2009	cutaneous melanoma	Gustave Roussy, Cancer Campus, Grand Paris	Unknown	No outcome recorded
Phase 1/2	NCT00402116	Sep 2006 → Dec 2009	gliosarcoma	Eli Lilly and Company	Completed	No outcome recorded
Phase 1/2	NCT00376103	Aug 2006 → Mar 2008	glioblastoma	Methodist Healthcare - Memphis	Terminated	No outcome recorded Stop: Business
Phase 1/2	NCT00492141	Jun 2006 → May 2007	Ewing sarcoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00304200	Mar 2006 → Oct 2007	metastatic melanoma	Northern California Melanoma Center	Terminated	No outcome recorded Stop: Business
Phase 1/2	NCT00311857	Feb 2006 → ?	glioblastoma	Heidelberg University	Unknown	No outcome recorded
Phase 1/2	NCT00128700	Jun 2005 → Nov 2007	central nervous system neoplasm	European Organisation for Research and Treatment of Cancer - EORTC	Completed	No outcome recorded
Phase 1/2	NCT00275067	May 2005 → May 2021	central nervous system neoplasm	Northwestern University	Unknown	No outcome recorded
Phase 1/2	NCT00085254	Apr 2005 → Nov 2012	adult glioblastoma, giant cell glioblastoma, gliosarcoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT00301067	Jan 2005 → Apr 2012	metastatic melanoma	Northwestern University	Completed	No outcome recorded
Phase 1/2	NCT00362817	Oct 2004 → Jan 2008	metastatic malignant neoplasm in the brain	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00068250	Jul 2003 → Dec 2016	central nervous system neoplasm, lymphoma	Radiation Therapy Oncology Group	Completed	Met primary
Phase 1/2	NCT00512798	Jun 2003 → Jul 2006	cancer, central nervous system neoplasm, melanoma	Vanderbilt-Ingram Cancer Center	Terminated	No outcome recorded
Phase 1/2	NCT00667953	Jan 2003 → Mar 2011	melanoma	Abramson Cancer Center at Penn Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00050986	Dec 2002 → Oct 2008	glioblastoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00026494	Jul 2001 → Apr 2008	metastatic malignant neoplasm	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00014105	Dec 2000 → ?	central nervous system neoplasm	Atlantic Health System	Unknown	No outcome recorded
Phase 1/2	NCT00005952	Aug 2000 → Nov 2005	central nervous system neoplasm, childhood germ cell tumor, head and neck cancer, kidney cancer +4	Duke University	Completed	No outcome recorded
Phase 1/2	NCT00005815	Dec 1999 → Aug 2004	cutaneous melanoma, ocular melanoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00021307	? → Apr 2002	central nervous system neoplasm	Fox Chase Cancer Center	Withdrawn	No outcome recorded

Phase 2346 trials · 15 met primary · 28 missed
Phase 2	NCT07807878	Jun 2027 → Jan 2030 expected	cutaneous melanoma	Assistance Publique Hopitaux De Marseille	Not yet recruiting	No outcome recorded
Phase 2	NCT07708961	Aug 2026 → Aug 2036	IDH-wildtype glioblastoma	Mayo Clinic	Suspended	No outcome recorded
Phase 2	NCT07698054	Aug 2026 → Jan 2030 expected	small cell lung carcinoma	Henan Cancer Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT07492680	Jul 2026 → Aug 2028 expected	cancer	Bristol-Myers Squibb	Recruiting	No outcome recorded
Phase 2	NCT06202066	Jul 2026 → Oct 2027 expected	cancer, lung neuroendocrine neoplasm, pancreatic neuroendocrine neoplasm	Roswell Park Cancer Institute	Recruiting	No outcome recorded
Phase 2	NCT07439172	Jul 2026 → Sep 2028 expected	astrocytoma (excluding glioblastoma), glioblastoma, oligodendroglioma	The Cooper Health System	Recruiting	No outcome recorded
Phase 2	NCT07501104	May 2026 → Sep 2029 expected	melanoma	Shanghai Zhongshan Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT05128734	Apr 2026 → Apr 2028 expected	triple-negative breast carcinoma	AHS Cancer Control Alberta	Not yet recruiting	No outcome recorded
Phase 2	NCT07457775	Mar 2026 → Jan 2028 expected	soft tissue sarcoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	Not yet recruiting	No outcome recorded
Phase 2	NCT07444918	Mar 2026 → Dec 2027 expected	childhood malignant neoplasm	Tianjin Medical University Cancer Institute and Hospital	Not yet recruiting	No outcome recorded
Show all 346 trials opens the full record — a long page
Phase 2/39 trials · 1 missed
Phase 2/3	NCT05685004	Dec 2023 → Nov 2030 expected	brain glioblastoma	TVAX Biomedical	Active not recruiting	No outcome recorded
Phase 2/3	NCT05432791	Mar 2023 → Aug 2024 overdue	leiomyosarcoma of the corpus uteri	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2/3	NCT04244708	Feb 2020 → Dec 2022	pituitary gland adenoma	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 2/3	NCT03732482	Mar 2019 → Jan 2022	non-small cell lung carcinoma	Taizhou Hospital	Unknown	No outcome recorded
Phase 2/3	NCT04316039	Apr 2018 → Apr 2023 overdue	low grade glioma	West China Hospital	Recruiting	No outcome recorded
Phase 2/3	NCT02772107	Dec 2015 → Jun 2017	small cell lung carcinoma	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 2/3	NCT02152982	Dec 2014 → Dec 2021 overdue	gliosarcoma	National Cancer Institute (NCI)	Active not recruiting	Missed primary
Phase 2/3	NCT01236560	Jan 2011 → Jun 2023	brain stem glioma, childhood cerebellar astrocytic neoplasm, childhood cerebral astrocytoma, childhood spinal cord tumor	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2/3	NCT00749723	Feb 2006 → Jan 2015	ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumor	University Hospital, Bonn	Completed	No outcome recorded
Phase 348 trials · 3 met primary · 8 missed
Phase 3	NCT07591493	Sep 2026 → Jun 2035 expected	pancreatic neuroendocrine tumor	Gustave Roussy, Cancer Campus, Grand Paris	Not yet recruiting	No outcome recorded
Phase 3	NCT07613450	May 2026 → Jul 2029 expected	meningioma	Shanghai Runshi Pharmaceutical Technology Co., Ltd	Not yet recruiting	No outcome recorded
Phase 3	NCT07195591	Dec 2025 → Dec 2031 expected	glioblastoma	GT Medical Technologies, Inc.	Recruiting	No outcome recorded
Phase 3	NCT07375563	Nov 2025 → Dec 2026 expected	ganglioneuroblastoma, neuroblastoma	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Recruiting	No outcome recorded
Phase 3	NCT06419946	Feb 2025 → Dec 2031 expected	IDH-wildtype glioblastoma	Vastra Gotaland Region	Recruiting	No outcome recorded
Phase 3	NCT05439278	Feb 2025 → Dec 2028 expected	glioblastoma	Severance Hospital	Recruiting	No outcome recorded
Phase 3	NCT06490536	Oct 2024 → Mar 2026 overdue	colorectal cancer	IFOM ETS - The AIRC Institute of Molecular Oncology	Recruiting	No outcome recorded
Phase 3	NCT05789043	Mar 2023 → Aug 2026 overdue	cutaneous melanoma	Peking University Cancer Hospital & Institute	Recruiting	No outcome recorded
Phase 3	NCT05868707	Mar 2023 → Mar 2026 overdue	melanoma	Binhui Biopharmaceutical Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT05095376	Mar 2022 → Feb 2026 overdue	gliosarcoma	NRG Oncology	Active not recruiting	No outcome recorded
Phase 3	NCT05331521	Apr 2021 → Mar 2033 expected	oligodendroglioma	University Hospital Heidelberg	Recruiting	No outcome recorded
Phase 3	NCT04532229	Apr 2021 → Oct 2023	diffuse intrinsic pontine glioma	Biotech Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT04829097	Nov 2020 → Nov 2023	glioblastoma	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Unknown	No outcome recorded
Phase 3	NCT03763422	Mar 2020 → Dec 2021	low grade glioma	European Organisation for Research and Treatment of Cancer - EORTC	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT04164199	Dec 2019 → May 2026	cancer	BeOne Medicines	Completed	No outcome recorded
Phase 3	NCT04221035	Nov 2019 → Nov 2026 expected	neuroblastoma	Gustave Roussy, Cancer Campus, Grand Paris	Recruiting	No outcome recorded
Phase 3	NCT03663725	Mar 2019 → Jun 2027 expected	glioblastoma	Centre Oscar Lambret	Active not recruiting	No outcome recorded
Phase 3	NCT03778541	Dec 2018 → Dec 2022	metastatic malignant neoplasm in the brain	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 3	NCT03243461	Jul 2018 → Dec 2023	anaplastic astrocytoma, diffuse midline glioma, H3 K27M-mutant, glioblastoma, gliomatosis cerebri	University of Göttingen	Unknown	No outcome recorded
Phase 3	NCT03632135	May 2018 → Jun 2022	glioblastoma	Cordgenics, LLC	Completed	Met primary
Phase 3	NCT03633552	Mar 2018 → Mar 2021	anaplastic astrocytoma, brain glioblastoma	Mashhad University of Medical Sciences	Unknown	No outcome recorded
Phase 3	NCT02685605	Dec 2016 → Nov 2025 overdue	glioblastoma	University Medical Center Mannheim	Active not recruiting	Missed primary
Phase 3	NCT02761070	Jul 2016 → Nov 2025	glioblastoma	Kyorin University	Unknown	No outcome recorded
Phase 3	NCT05600491	Nov 2015 → Dec 2022	anaplastic oligoastrocytoma, glioblastoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 3	NCT02313389	Sep 2015 → Apr 2023	primary central nervous system lymphoma	Assistance Publique - Hôpitaux de Paris	Unknown	No outcome recorded
Phase 3	NCT03435302	Feb 2014 → Feb 2018	melanoma	Peking University Cancer Hospital & Institute	Unknown	No outcome recorded
Phase 3	NCT01765088	Sep 2012 → Dec 2017	anaplastic astrocytoma, anaplastic oligoastrocytoma, glioblastoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 3	NCT01649830	Jul 2012 → Aug 2025 overdue	low-grade astrocytoma, oligoastrocytoma, oligodendroglioma	Sun Yat-sen University	Recruiting	No outcome recorded
Phase 3	NCT00978458	Nov 2009 → Dec 2026 expected	central nervous system neoplasm, poisoning	Eastern Cooperative Oncology Group	Active not recruiting	No outcome recorded
Phase 3	NCT01014767	Nov 2009 → Oct 2013	brain cancer, choroid plexus neoplasm	Tufts Medical Center	Terminated	No outcome recorded
Phase 3	NCT00887146	Sep 2009 → Oct 2029 expected	central nervous system neoplasm	Alliance for Clinical Trials in Oncology	Active not recruiting	No outcome recorded
Phase 3	NCT00897377	Dec 2007 → ?	low-grade astrocytoma, oligoastrocytoma, oligodendroglioma	Sun Yat-sen University	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01364064	Jan 2007 → Jun 2008	glioblastoma	King Faisal Specialist Hospital & Research Center	Completed	No outcome recorded
Phase 3	NCT00820963	Jul 2006 → May 2011	central nervous system neoplasm	Centre Leon Berard	Completed	No outcome recorded
Phase 3	NCT00304031	Jan 2006 → Feb 2011	central nervous system neoplasm	Radiation Therapy Oncology Group	Completed	Missed primary
Phase 3	NCT00182819	Jul 2005 → Aug 2013	central nervous system neoplasm	European Organisation for Research and Treatment of Cancer - EORTC	Completed	Missed primary
Phase 3	NCT00268684	May 2005 → ?	metastatic neoplasm, non-small cell lung carcinoma	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
Phase 3	NCT00335075	Mar 2005 → Feb 2006	astrocytoma (excluding glioblastoma), glioblastoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT01502241	Jan 2005 → Nov 2010	anaplastic astrocytoma, glioblastoma	Heidelberg University	Completed	Met primary
Phase 3	NCT00091572	Oct 2004 → Dec 2007	melanoma	Merck Sharp & Dohme LLC	Completed	Missed primary
Phase 3	NCT00096265	Oct 2004 → Jun 2011	metastatic malignant neoplasm in the brain, non-small cell lung carcinoma	National Cancer Institute (NCI)	Terminated	Missed primary
Phase 3	NCT00392886	Mar 2004 → Dec 2010	central nervous system neoplasm	Children's Hospital Los Angeles	Unknown	No outcome recorded
Phase 3	NCT00068952	Aug 2003 → Mar 2006	glioblastoma	Pfizer	Completed	No outcome recorded
Phase 3	NCT00052455	Oct 2002 → Sep 2010	central nervous system cancer	Institute of Cancer Research, United Kingdom	Completed	Missed primary
Phase 3	NCT00020839	Apr 2001 → May 2003	cutaneous melanoma, metastatic malignant neoplasm	European Organisation for Research and Treatment of Cancer - EORTC	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00006353	Jul 2000 → Mar 2002	central nervous system neoplasm	European Organisation for Research and Treatment of Cancer - EORTC	Completed	Met primary
Phase 3	NCT00004259	Jun 2000 → Feb 2015	central nervous system neoplasm	Radiation Therapy Oncology Group	Completed	Missed primary
Phase 3	NCT00717210	Jun 1999 → Feb 2005	anaplastic astrocytoma, oligoastrocytoma, oligodendroglioma	Neuro-Oncology Working Group of the German Cancer Society	Completed	Missed primary

Phase 42 trials · 1 met primary
Phase 4	NCT02496988	Jul 2015 → Jul 2028 expected	malignant glioma	The First People's Hospital of Changzhou	Not yet recruiting	No outcome recorded
Phase 4	NCT00686725	Jun 2008 → Sep 2011	glioblastoma	Merck Sharp & Dohme LLC	Completed	Met primary
Phase not applicable19 trials · 1 met primary
—	NCT07191431	Sep 2025 → Sep 2027 expected	central nervous system non-hodgkin lymphoma	Ruijin Hospital	Recruiting	No outcome recorded
—	NCT04199026	Feb 2025 → Dec 2028 expected	sarcoma	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
—	NCT06832267	Feb 2025 → Feb 2027 expected	primary central nervous system lymphoma	Zhejiang Cancer Hospital	Recruiting	No outcome recorded
—	NCT06553781	Sep 2024 → Sep 2025 overdue	melanoma	Fudan University	Not yet recruiting	No outcome recorded
—	NCT06381726	Mar 2024 → Feb 2028 expected	malignant glioma	University of Milan	Recruiting	No outcome recorded
—	NCT06445257	Sep 2023 → Apr 2026	primary central nervous system lymphoma	Huai'an First People's Hospital	Unknown	No outcome recorded
—	NCT05204524	Aug 2021 → Aug 2022	leiomyosarcoma	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
—	NCT03257618	Jul 2017 → Nov 2021	glioma	Institut du Cancer de Montpellier - Val d'Aurelle	Completed	No outcome recorded
—	NCT03780569	Apr 2017 → Jan 2019	glioblastoma	NovoCure Ltd.	Unknown	No outcome recorded
—	NCT02567539	May 2015 → Jun 2022	glioma	Istituto Clinico Humanitas	Completed	No outcome recorded
—	NCT02416999	May 2015 → May 2018	malignant glioma	Hebei Yanda Hospital	Unknown	No outcome recorded
—	NCT03082846	Jan 2014 → Nov 2016	glioma	Xue Xiaoying	Completed	No outcome recorded
—	NCT01478854	Dec 2011 → Apr 2018	glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
—	NCT01342757	Dec 2010 → May 2012	adult glioblastoma, brain neoplasm, depressive disorder	National Cancer Institute (NCI)	Completed	No outcome recorded
—	NCT01702610	Dec 2008 → Dec 2014	glioblastoma	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
—	NCT00253487	Aug 2005 → Aug 2012	central nervous system neoplasm	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
—	NCT00109798	Mar 2005 → Jul 2006	central nervous system neoplasm, lymphoma	The Methodist Hospital Research Institute	Withdrawn	No outcome recorded
—	NCT00077207	Jul 2004 → Mar 2010	brain neoplasm	Children's Oncology Group	Completed	Met primary
—	NCT00416819	Sep 2003 → Dec 2005	central nervous system neoplasm, lymphoma	University of California, San Francisco	Completed	No outcome recorded

Comparator or background therapy333 trials
Phase 0	NCT06831526 Background	Nov 2025 → Feb 2029 expected	glioblastoma	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 0	NCT06072586 Background	Oct 2023 → Dec 2026 expected	glioblastoma	St. Joseph's Hospital and Medical Center, Phoenix	Recruiting	No outcome recorded
Phase 0	NCT05634707 Comparator	Aug 2023 → Dec 2026 expected	malignant glioma, primary brain neoplasm	Duke University	Active not recruiting	No outcome recorded
Phase 0	NCT05589961 Background	Oct 2022 → Jul 2024	glioblastoma	The Second Hospital of Hebei Medical University	Unknown	No outcome recorded
Phase 0	NCT03554707 Background	Jun 2022	central nervous system cancer	SynerGene Therapeutics, Inc.	Withdrawn	No outcome recorded Stop: Enrollment
Show all 333 trials opens the full record — a long page

Press releases naming this drug 16 releases

Date	Issuer	Release
2026-02-03	Allarity Therapeutics	Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment allarity.com ↗
2025-03-06	Allarity Therapeutics	Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration allarity.com ↗
2022-11-14	MimiVax, LLC	Phase 2a Trial of SurVaxM Plus Temozolomide for Newly Diagnosed Glioblastoma mimivax.com ↗
2021-05-31	BioDlink Biopharm Co., Ltd.	TOT BIOPHARM’s Temozolomide Capsules (TOZ309) Approved for Marketing biodlink.com ↗
2018-10-22	BeOne Medicines	BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress beonemedicines.com ↗
2017-07-14	Zydus Lifesciences Limited	Zydus receives final approval from the USFDA for Temozolomide Capsules and Nadolol Tablets USP zyduslife.com ↗
2015-08-18	Merck Sharp & Dohme LLC	Merck Recalls TEMODAR® and Temozolomide Bottles with Cracked Caps Due to Failure to Meet Child–Resistant Closure Requirement merck.com ↗
2014-04-29	Karyopharm Therapeutics Inc	Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide (KING Study) karyopharm.com ↗
2014-02-13	Sun Pharmaceutical Industries, Inc.	Sun Pharma announces US FDA approval for generic Temodar® sunpharma.com ↗
2013-08-12	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Pharmaceuticals and Perrigo Company Announce the U.S. Launch of Generic Temozolomide tevapharm.com ↗
2013-08-12	Perrigo Company	Teva Pharmaceuticals And Perrigo Company Announce The U.S. Launch Of Generic Temozolomide perrigo.com ↗
2012-03-21	Perrigo Company	Perrigo Announces Australian Approval for Generic Temozolomide perrigo.com ↗
2010-11-09	Merck Sharp & Dohme LLC	Merck Wins TEMODAR® Patent Infringement Lawsuit on Appeal merck.com ↗
2010-03-17	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Provides Update on Generic Temodar® tevapharm.com ↗
2010-01-26	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives Favorable Court Decision Regarding Generic Temodar® tevapharm.com ↗
2007-05-29	CASI pharmaceuticals, Inc.	EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients issuerdirect.com ↗

Evidence & citations 19 cited values

Every value below carries the sentence it was read from. 1,042 sources stand behind the page.

Field	Value	Cited text
Known as	temozolomide	“The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the...” NCT04250922 ↗ 978 “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Carboplatin; * Irinotecan; * Etoposide; *...” NCT03632135 ↗ “This is a Phase 2, open-label, multicenter study to assess the PFS-6m of E7016 at the selected dose of 320-mg once daily (QD) in combination with 150-mg/m2 of Temozolomide...” NCT01605162 ↗ “The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin,...” NCT04135807 ↗ “The Nordic Lymphoma Group has conducted a phase ll trial in newly diagnosed primary central nervous system lymphoma patients applying an age-adjusted multi-agent...” PMID 25480497 ↗ Dec 2014 “Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous...” NCT02399189 ↗ “The "alkylating-based" group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or...” NCT03217097 ↗ “A Randomized, Controlled, Open-label, Multicenter Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of KH617 in Combination With Temozolomide Versus Investigator's...” NCT07138001 ↗ “Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1...” NCT04532229 ↗ “Temozolomide 75mg/m2 orally once daily (usually administered the night preceding each radiation session) starting the evening before the first radiation session over a period...” NCT03393000 ↗ “Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no...” NCT06477939 ↗ Show 968 more sources
Known as	benzolamide	“Drug Therapy with Temozolomide (benzolamide) (Standard of Care)” NCT04209790 ↗
Known as	SCH 52365	“Continuous Temozolomide (SCH 52365) in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer, Phase II” NCT00194766 ↗ 2 “Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme” NCT00006358 ↗ “temozolomide (SCH 52365, Temodar (R))” NCT00005637 ↗
Known as	Temodal	“Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas” NCT00003718 ↗ 4 “only Temodal® capsules must be used to generate a temozolomide suspension” NCT03243461 ↗ NCT01022918 ↗ NCT00991250 ↗ NCT06258018 ↗
Known as	Temodar	“On March 15, 2005, the U.S. Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with...” PMID 16203762 ↗ Oct 2005 20 “One currently used drug called Temozolomide (Temodar) has been shown to be active in human brain tumors but its actual central nervous system (CNS) penetration is unknown.” NCT01180816 ↗ “Temozolomide (Temodar) is an anti-cancer drug that works by interfering with the growth of cells (including cancer cells) by stopping their division.” NCT00590681 ↗ “Temozolomide (Temodar) is an FDA approved medication for the treatment of newly diagnosed glioblastomas.” NCT00657267 ↗ “Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma” NCT00006025 ↗ “Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.” NCT01107522 ↗ “The product label for temozolomide (Temodar®) provides the following dosing information.” NCT03149575 ↗ “With Irinotecan (CPT-11) (NSC- #6616348) Plus Temodar (NSC #362856)” NCT00005951 ↗ “Temodar® (temozolomide)” NCT00409383 ↗ “Temodar (Temozolomide)” NCT01067066 ↗ “Temozolomide (temodar)” NCT00846430 ↗ Show 10 more sources
Known as	Temodar (R)	“temozolomide (SCH 52365, Temodar (R))” NCT00005637 ↗
Known as	Temodar (temozolomide [TMZ])	“Temodar (temozolomide [TMZ])” NCT02254954 ↗
Known as	Temodar-Temozolomide	“Temodar - Temozolomide” NCT00616005 ↗ 5 “Temodar - Temozolomide” NCT00613093 ↗ “Temodar (Temozolomide)” NCT00249964 ↗ “Temodar (temozolomide)” NCT01186406 ↗ “Temodar - Temozolomide” NCT00610571 ↗ “Temodar-Temozolomide” NCT00612638 ↗
Known as	Temozolomid	“Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks” NCT00004106 ↗
Known as	Temozolomide (TMZ)	“Temozolomide (TMZ)” NCT06504381 ↗
Known as	Temozolomide - Temodar	“Temozolomide - Temodar” NCT00612339 ↗ 2 “Temozolomide (Temodar)” NCT01044966 ↗ “Temozolomide (Temodar)” NCT00939991 ↗
Known as	Temozolomide Injection	“Drug: Temozolomide Injection” NCT05512481 ↗
Known as	Temozolomide is also known as Temodar	“Temozolomide is also known as Temodar” NCT00304200 ↗
Known as	temozolomide, temodar/temodal	“temozolomide, temodar/temodal” NCT01113957 ↗
Known as	TMZ	“PURPOSE: We performed a phase 2 trial of neoadjuvant temozolomide (TMZ), followed by hypofractionated accelerated radiation therapy (HART) with concurrent TMZ, and adjuvant TMZ...” PMID 28011051 ↗ Nov 2016 157 “The European Organization for Research and Treatment of Cancer (EORTC) 26981-22981/National Cancer Institute of Canada (NCIC) CE.3 clinical trial database of radiotherapy (RT)...” PMID 21880994 ↗ Aug 2011 “PURPOSE: This pediatric phase I trial of O6-benzylguanine (O6BG) and temozolomide (TMZ) on a daily schedule for 5 days, every 28 days was performed to determine the...” PMID 16234526 ↗ Oct 2005 “To evaluate the clinical efficacy of adding temozolomide (TMZ) to preoperative capecitabine (CAP)-based chemoradiotherapy in patients with locally advanced rectal cancer (LARC)...” PMID 36376167 ↗ Nov 2022 “Adults with newly diagnosed uMGMT glioblastoma and Karnofsky performance status (KPS) ≥70 were randomly assigned to radiotherapy with either immunotherapy (ipi and nivo) or...” PMID 40779733 ↗ Aug 2025 “This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and...” PMID 19289491 ↗ Mar 2009 “This is a Phase 2, open-label, multicenter study to assess the PFS-6m of E7016 at the selected dose of 320-mg once daily (QD) in combination with 150-mg/m2 of Temozolomide...” NCT01605162 ↗ “This study will test the hypothesis that prolonged adjuvant Temozolomide (TMZ) may delay relapses in patients with glioblastoma compared to the standard care consisting in...” NCT00643825 ↗ “BACKGROUND: Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients...” PMID 35419607 ↗ Jan 2023 “Carboxyamidotriazole orotate (CTO) is a novel oral inhibitor of non-voltage-dependent calcium channels with modulatory effects in multiple cell-signaling pathways and...” PMID 29683790 ↗ Apr 2018 “This randomised phase II study evaluated the use of Temozolomide (TMZ) concomitant with 30 Gray (Gy) of Whole-brain irradiation (WBI) for 2 weeks without adjuvant TMZ vs. WBI...” PMID 22257825 ↗ Jan 2012 Show 147 more sources
Action	Inhibit	“Temozolomide's inhibition of AGT” PMID 20511167 ↗ Jun 2010
Modality	Small molecule	“Temozolomide is an alkylating agent” PMID 18626572 ↗ Jul 2008
Route	Oral	“administered orally” PMID 12763216 ↗ Jun 2003
Target	AGT	“Temozolomide's inhibition of AGT may sensitize leukemia cells” PMID 20511167 ↗ Jun 2010